$435.64
Value $235B
AMGN and PRLD stock compared: price, dividend, valuation and results, from SEC filings.
$435.64
Value $235B
$3.23
Value $333M
Amgen (AMGN) has a market value of $235B and Prelude Therapeutics (PRLD) $333M. Over the last year, with dividends, AMGN moved +31.5% and PRLD +93.4%. Dividend yield: AMGN 2.31%, PRLD none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMGN$235B
PRLD$333M
AMGN is 705 times PRLD
Revenue, 12 months
AMGN$38.9B
PRLD$22M
AMGN is 1,803 times PRLD
Net income, 12 months
AMGN$9.4B
PRLD-$53M
Operating margin
AMGN32.4%
PRLD-283.9%
316.3 points apart
ROIC
AMGN16.2%
PRLD-54.3%
70.5 points apart
P/E
AMGN25.0
PRLD–
Dividend yield
AMGN2.3%
PRLD0.0%
2.3 points apart
5-year return
AMGN+146.3%
PRLD-77.7%
224.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMGN+146.4%
PRLD-77.7%
| Period | AMGNWith dividends | PRLDWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +31.5%Price +27.2% | +93.4%Price +93.4% |
| 3 years since November 20, 2023 | +79.2%+21.5% a yearPrice +64.2% | -6.1%-2.1% a yearPrice -6.1% |
| 5 years since November 19, 2021 | +146.3%+19.8% a yearPrice +111.4% | -77.7%-25.9% a yearPrice -77.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMGNAmgenPRLDPrelude Therapeutics
| Price | $435.64 | $3.23 |
|---|---|---|
| Market value | $235B | $333M |
| Enterprise value (EV) | $276B | $193M |
| P/E | 25.0 | – |
| P/E, 5-year median | 23.0 | – |
| P/B | 16.4 | 2.7 |
| EV/EBIT | 21.9 | – |
| Free cash flow yield | 4.1% | – |
| Revenue, 12 months | $38.9B | $22M |
|---|---|---|
| Net income, 12 months | $9.4B | -$53M |
| Free cash flow, 12 months | $9.6B | -$28M |
| Earnings per share, 12 months | $17.25 | -$0.59 |
| Revenue growth, year on year | 10.0% | 73.4% |
| Revenue growth a year, past | +7.6%over 5 years | +73.4%over 1 years |
| EPS growth a year, past | +2.9%over 5 years | – |
| Gross margin | 70.9% | – |
|---|---|---|
| Operating margin | 32.4% | -283.9% |
| Net margin | 24.1% | -247.1% |
| ROIC | 16.2% | -54.3% |
| ROE | 87.8% | -59.9% |
| Cash | $13.2B | $140M |
|---|---|---|
| Total debt | $54.0B | $18M |
| Net debt / EBITDA | 2.3 | – |
| Interest cover | 4.8× | – |
| Dividend yield | 2.3% | – |
|---|---|---|
| Dividend per share, 12 months | $10.08 | – |
| Dividend growth a year, past | +8.1%over 5 years | – |
| Buyback yield | – | – |
| Shareholder yield | 2.3% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($235B) is about 705.3 times Prelude Therapeutics ($333M), at today's prices.
Since November 19, 2021, AMGN's price moved +111.4% and PRLD's -77.7%. With dividends: AMGN +146.3% (+19.8% a year), PRLD -77.7% (-25.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.31% for Amgen and none for Prelude Therapeutics. Over the last twelve months they paid $10.08 and – per share.
Over the last twelve months, the net margin was 24.1% for Amgen and -247.1% for Prelude Therapeutics, and the operating margin 32.4% and -283.9%. Revenue was $38.9B and $22M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.